Q-omics provides the consensus-scored PGAM5 profile across patient tissues and cancer cell-line models. PGAM5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PGAM5 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, PGAM5 protein abundance shows 21,556 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where PGAM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM5 survival associations across molecular data types. PGAM5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM5 RNA expression–survival associations across cancer types. High PGAM5 expression shows unfavorable associations in LIHC, UVM, MESO, KIRC, KICH and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PGAM5 RNA expression.
This table summarizes PGAM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PGAM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM5 shows higher tumor expression in BLCA, COAD, LUAD, HNSC, KIRP and LIHC. The BLCA box plot shows higher PGAM5 RNA expression in tumor versus normal tissue (log2 FC = +1.389, t-test p < 0.001).
This table shows molecular features associated with PGAM5 in patient tissues and cancer cell lines. In patient samples, PGAM5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PGAM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
